MENU

LTRN Stock Lantern Pharma (LTRN, $3.44) Aroon Indicator entered a Downtrend on October 18, 2024.

A.I.dvisor
at Tickeron.com
10/19/24
Loading...
LTRN - Lantern Pharma
Aroon signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Aroon signal
Price: $3.44
Daily change: +$0.05 (+1.47%)
Daily volume: 17.1K
Industry: Biotechnology
For the last three days, A.I.dvisor has detected that LTRN's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for LTRN, and traders may view it as a Sell signal for the next month. Traders may consider selling the stock or exploring put options. A.I.dvisor backtested this indicator and found 223 similar cases, of which were successful. Based on this data, the odds of success are

LTRN's Indicator enters downward trend

The Aroon Indicator for LTRN entered a downward trend on October 18, 2024. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 223 similar instances where the Aroon Indicator formed such a pattern. In of the 223 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 27, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on LTRN as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LTRN turned negative on October 02, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LTRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where LTRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LTRN advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .

LTRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.277) is normal, around the industry mean (12.594). P/E Ratio (0.000) is within average values for comparable stocks, (111.595). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.971). LTRN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (224.025).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LTRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LTRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
LTRN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1920 McKinney Avenue
Phone
+1 972 277-1136
Employees
21
Web
https://www.lanternpharma.com